Pharmacological thromboprophylaxis and total hip or knee replacement

British Journal of Nursing : BJN
S P Frostick

Abstract

Pharmacological and mechanical thromboprophylaxis reduces the risk of venous thromboembolism (VTE) in patients undergoing total knee/hip replacement (TKR/THR). Nurses play a key role in VTE prevention through clinical care, before and after discharge from hospital, and patient education. Conventional pharmacological agents for VTE prophylaxis include low molecular weight heparins (LMWHs) and fondaparinux. However, parenteral administration, increased bleeding risk, and patient/physician non-adherence to treatment and guidelines, are important limitations. Three non-vitamin K antagonist oral anticoagulants--dabigatran etexilate, rivaroxaban and apixaban--are available in the UK for VTE prevention following THR/TKR. In common with LMWHs and fondaparinux, these offer rapid onset of action and fixed doses without the need for routine coagulation monitoring. An agent for emergency reversal of dabigatran is in development, while there is no antidote for fondaparinux and LMWHs can be partially neutralised by protamine. Oral administration may result in better adherence to treatment and guidelines, reducing the nurse burden after discharge, and enhancing cost-effectiveness.

References

Jul 29, 1998·Archives of Internal Medicine·R H WhiteW Bargar
Nov 12, 2003·Archives of Internal Medicine·Theodore E WarkentinJohn G Kelton
Mar 24, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Isabelle Gouin-ThibaultVirginie Siguret
Nov 2, 2005·Journal of the Royal Society of Medicine·S T RashidA A Shlebak
Dec 7, 2005·Clinical Orthopaedics and Related Research·Vincent D PellegriniC McCollister Evarts
Feb 25, 2006·The Journal of Bone and Joint Surgery. British Volume·B T BjørnaråO E Dahl
Aug 15, 2006·Clinical Orthopaedics and Related Research·Vincent D PellegriniC McCollister Evarts
Apr 4, 2007·The Journal of Bone and Joint Surgery. American Volume·Steven KurtzMichael Halpern
Jun 27, 2008·The New England Journal of Medicine·Bengt I ErikssonUNKNOWN RECORD1 Study Group
Jun 27, 2008·The New England Journal of Medicine·Michael R LassenUNKNOWN RECORD3 Investigators
Oct 9, 2008·Archives of Orthopaedic and Trauma Surgery·L C Borris
Aug 7, 2009·The New England Journal of Medicine·Michael Rud LassenRonald J Portman
Jan 12, 2010·Thrombosis and Haemostasis·Jeffrey I Weitz
Mar 25, 2010·Clinical Orthopaedics and Related Research·Thomas WilkeAndreas Kurth
Dec 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Thomas Wilke, Sabrina Müller
Dec 24, 2010·The New England Journal of Medicine·Michael Rud LassenUNKNOWN ADVANCE-3 Investigators
Mar 15, 2012·Chest·Gordon H GuyattUNKNOWN American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel
Nov 6, 2014·The New England Journal of Medicine·Jack E AnsellJames C Costin
May 29, 2015·Thrombosis and Haemostasis·Charles V PollackJeffrey I Weitz
Jun 23, 2015·The New England Journal of Medicine·Charles V PollackJeffrey I Weitz

❮ Previous
Next ❯

Citations

Sep 14, 2018·Journal of Perioperative Practice·Arijit Ghosh, Urjit Chatterji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.